All In Biotech

Drug Trial Radar · NCT04201093

Fixed-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)

Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 529 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

529

Actual

Start

Dec 13, 2019

Primary completion

Jun 28, 2024

Study completion Jun 28, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.

Conditions

  • Parkinson Disease

Interventions

  • TavapadonDrug

    Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.

  • PlaceboDrug

    Participants will receive placebo matching to tavapadon QD orally for 27 weeks.

  • TavapadonDrug

    Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the MDS-UPDRS Parts II and III Combined ScoreTime frame: Week 26

Locations

77 sites in 12 countries. Site status is shown where the registry gives one.

  • Birmingham, Alabama

    Birmingham, Alabama

  • Little Rock, Arkansas

    Little Rock, Arkansas

  • Fountain Valley, California

    Fountain Valley, California

  • Los Angeles, California

    Los Angeles, California

  • Pasadena, California

    Pasadena, California

  • Englewood, Colorado

    Englewood, Colorado

  • Adventura, Florida

    Adventura, Florida

  • Boca Raton, Florida

    Boca Raton, Florida

  • Tampa, Florida

    Tampa, Florida

  • Augusta, Georgia

    Augusta, Georgia

  • Savannah, Georgia

    Savannah, Georgia

  • Chicago, Illinois

    Chicago, Illinois

  • Kansas City, Kansas

    Kansas City, Kansas

  • Scarborough, Maine

    Scarborough, Maine

  • Boston, Massachusetts

    Boston, Massachusetts

  • East Lansing, Michigan

    East Lansing, Michigan

  • Las Vegas, Nevada

    Las Vegas, Nevada

  • Asheville, North Carolina

    Asheville, North Carolina

  • Durham, North Carolina

    Durham, North Carolina

  • Columbus, Ohio

    Columbus, Ohio

  • Toledo, Ohio

    Toledo, Ohio

  • Philadelphia, Pennsylvania

    Philadelphia, Pennsylvania

  • Georgetown, Texas

    Georgetown, Texas

  • Houston, Texas

    Houston, Texas

  • Lubbock, Texas

    Lubbock, Texas

  • Burlington, Vermont

    Burlington, Vermont

  • Virginia Beach, Virginia

    Virginia Beach, Virginia

  • Erina, New South Wales

    Erina, New South Wales, Australia

  • Woolloongabba, Queensland

    Woolloongabba, Queensland, Australia

  • Parkville, Victoria

    Parkville, Victoria, Australia

  • Medical center VITA1, Pleven

    Pleven, Bulgaria

  • Pleven, Bulgaria

    Pleven, Bulgaria

  • Pleven

    Pleven, Bulgaria

  • Multiprofile Hospital, Sofia

    Sofia, Bulgaria

  • Sofia

    Sofia, Bulgaria

  • Sofia

    Sofia, Bulgaria

  • DCC Neoclinic

    Sofia, Bulgaria

  • Sofia

    Sofia, Bulgaria

  • Ottawa, Ontario

    Ottawa, Ontario, Canada

  • Toronto, Ontario

    Toronto, Ontario, Canada

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.